LENSAR, Inc.

NASDAQ•LNSR

CEO: Mr. Nicholas T. Curtis

セクター: Healthcare

業種: Medical - Devices

上場日: 2020-10-02

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

連絡先情報

2800 Discovery Drive, Orlando, FL, 32826, United States

888-536-7271

www.lensar.com

時価総額

$139.45M

PER (TTM)

-2.7

配当利回り

52週高値

$17.31

52週安値

$9.46

52週レンジ

28%

順位44Top 53.8%

3.7

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 3.7 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$14.32M+5.74%

直近4四半期の推移

EPS

-$0.31+138.46%

直近4四半期の推移

フリーCF

-$3.51M-212.13%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Revenue reached $42.4M for nine months, up 15%, driven by increased ALLY System placements and procedure volume.

Product Revenue Surge Product revenue increased 21% to $33.2M over nine months, primarily attributed to higher procedure volume growth of $4.3M.

Recurring Revenue Base Recurring revenue streams comprised 79% of total revenue for the nine-month period ending September 30, 2025.

Financing Inflow Noted Net cash provided by financing was $9.8M, primarily from the Alcon acquisition-related deposit received, supporting liquidity.

リスク要因

Merger Closing Uncertainty Alcon Merger consummation faces regulatory hurdles, including FTC Second Request review, potentially delaying Q1 2026 closing.

Widening Operating Losses Nine-month net loss widened to $(32.8M) versus $(12.7M) last year, reflecting ongoing operating cash outflows expected near-term.

SG&A Expense Spike SG&A expenses surged 77% to $34.8M for nine months due to $13.7M in acquisition-related costs incurred for the pending Merger.

Inflationary Cost Pressure Product cost of revenue rose 32% to $14.4M for nine months due to tariffs and inflation, negatively impacting gross margin.

見通し

Merger Closing Timeline Merger expected to close in Q1 2026, subject to HSR waiting period expiration and satisfaction of customary closing conditions.

ALLY System Regulatory Focus Future growth hinges on securing additional regulatory clearances for the ALLY System in international markets like China.

Future Capital Requirements Management expects revenue and SG&A expenses to increase, potentially necessitating future capital raises on acceptable terms.

Market Acceptance Strategy Success depends on maintaining market acceptance and effectively growing the U.S. sales organization and international distributor network.

同業比較

売上高 (TTM)

ARAY

$436.97M

-3.6%

ANIK

$112.82M

+3.8%

OWLT

$105.66M

+35.3%

粗利益率 (最新四半期)

SPRO

100.0%

+0.0pp

MXCT

92.4%

+16.1pp

SGHT

87.3%

+2.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANIK	$206.22M	-18.8	-7.4%	12.7%
SGHT	$195.50M	-5.0	-55.7%	35.0%
PROF	$167.94M	-3.7	-85.7%	3.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-5.1%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

25%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし